(BHC) Bausch Health Companies - Ratings and Ratios

Bausch Health Companies Inc. is a multifaceted healthcare entity that develops, produces, and distributes a broad spectrum of pharmaceuticals and medical devices across various therapeutic areas, including gastroenterology, neurology, dermatology, and eye health, both domestically and internationally. The companys diversified portfolio is managed through five distinct segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb, each focusing on specific product categories and markets.

The companys operational segments cater to different healthcare needs: Salix is focused on gastroenterology, International handles a wide range of products including aesthetic medical devices and pharmaceuticals globally, Solta Medical is dedicated to aesthetic medical devices, Diversified covers neurology, dermatology, and generic pharmaceuticals, among others, and Bausch + Lomb is a key player in vision care, surgical, and ophthalmic pharmaceuticals. This diversified approach allows Bausch Health to mitigate risks and capitalize on opportunities across different markets.

With its headquarters in Laval, Canada, Bausch Health Companies Inc. has evolved from its former identity as Valeant Pharmaceuticals International, Inc., rebranding in July 2018. The company maintains a significant online presence through its official website, https://www.bauschhealth.com, serving as a hub for information on its products, services, and investor relations.

Analyzing the and of BHC, we observe a complex picture. The stocks last price is $5.51, with its 20-day SMA at $4.71 and 50-day SMA at $4.88, indicating a recent uptrend. However, the 200-day SMA stands at $6.91, suggesting a longer-term downtrend. The ATR of 0.21 translates to a 3.80% volatility, which is relatively moderate. The stock is currently trading above its 52-week low of $4.32 but significantly below its 52-week high of $9.78. With a market cap of $2.036 billion and a forward P/E of 1.34, the stock appears undervalued. The Return on Equity (RoE) of 3.54% indicates a relatively low profitability level.

Forecasting BHCs future performance involves synthesizing its technical and fundamental data. Given the current trends, if BHC can sustain its price above the 50-day SMA and push towards the 200-day SMA, it could signal a potential reversal of the long-term downtrend. However, the low P/E and RoE suggest underlying challenges that need to be addressed for sustained growth. A potential catalyst could be a successful product launch or strategic acquisition that bolsters its pipeline and profitability. Therefore, a cautious outlook is warranted, with a potential target price in the range of $7-$8, contingent on positive developments and improved financial performance.